The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis

• Published in: Scientific reports Vol. 6; no. 1; p. 35770
• Main Authors: Ye, Sa, Li, Jiuke, Hao, Ke, Yan, Jianping, Zhou, Hongbin
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 27.10.2016; Nature Publishing Group
• Subjects: 692/4028/67/1059/602; 692/4028/67/1612/1350; Adenocarcinoma; Antineoplastic Agents - adverse effects; Antineoplastic Agents - pharmacology; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - pathology; Disease control; Disease-Free Survival; Drugs; Humanities and Social Sciences; Humans; Inhibitors; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Meta-analysis; Metastases; multidisciplinary; Non-small cell lung carcinoma; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - pharmacology; Proto-Oncogene Proteins c-met - antagonists & inhibitors; Science; Survival; Survival Analysis
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/srep35770

c-MET inhibitors are considered as a kind of novel drugs in non-small cell lung cancer (NSCLC) treatment. However, the results of different clinical studies involving c-MET inhibitors were not consistent. In this report, we performed Meta-analysis to investigate the beneficial and harmful effects of these drugs from 9 studies including 1611 patients in target drug groups and 1605 patients in control groups. As a result, patients in target drugs group had longer progression free survival (PFS) (HR 0.80, 95% CI 0.66–0.99, p = 0.04) but not overall survival (OS) than those in control group, especially in Asian (HR 0.57, 95% CI 0.42–0.76, p < 0.001), Non-squamous (HR 0.79, 95% CI 0.64–0.97, p = 0.03), Phase III (HR 0.66, 95% CI 0.50–0.86, p = 0.002), previous treated (HR 0.77, 95% CI 0.63–0.95, p = 0.01) and small molecular compounds subgroups (HR 0.62, 95% CI 0.50–0.78, p < 0.001). In addition, target drugs did not affect the objective response rate (ORR) but improved disease control rate (DCR) (RR 1.22, 95% CI 1.02–1.46, p = 0.03) of NSCLC patients. Our study first indicated that targeting c-MET therapies improved PFS and DCR in advanced or metastatic NSCLC patients, especially in previous treated Asian patients with adenocarcinoma.